Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Se deben a la accin de la semaglutida sobre los receptores de GLP-1 en el tracto digestivo (que regulan el vaciamiento gstrico) y en las regiones cerebrales del hipotlamo y el tronco del encfalo (que modulan el apetito y saciedad)
Your childs pediatrician will prescribe an appropriate dose if it is needed
Try the BMI Calculator Table of contents The 30-second answer The full SURMOUNT-1 dose-response data Why "highest dose = best" isn't always true The standard dose escalation schedule When to stop escalating: signs your current dose is working The 5 percent rule at month 3 and month 6 Why some patients don't need to reach 15 mg Side effects across the dose ladder Maintenance vs continued escalation FAQ The full SURMOUNT-1 dose-response data SURMOUNT-1 (Jastreboff et al., NEJM 2022) is the phase 3 registration trial that earned Zepbound its FDA approval for weight management
Please discuss this with your health care provider as you may need to implement other changes to manage your blood sugar levels if your provider approves the lower dosage
